Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study

Key Takeaways NVS reported that Cosentyx missed the primary endpoint in a phase III study for giant cell arteritis. Cosentyx plus a 26-week steroid taper showed no significant remission benefit over placebo and 52-week taper. While endpoints were missed, Cosentyx showed lower steroid exposure and consistent safety in the GCA study.Novartis (NVS) announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet the primary endpoint of sustained remission at week ...